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a b s t r a c t
Marek's disease virus (MDV) is a representative alpha herpes virus able to induce rapid-onset T-cell
lymphoma in its natural host and regarded as an ideal model for the study of virus-induced
tumorigenesis. Recent studies have shown that the mdv1-miR-M4-5p, a viral analog of cellular miR-
155, is critical for MDV's oncogenicity. However, the precise mechanism whereby it was involved in MD
lymphomagenesis remained unknown. We have presently identiﬁed the host mRNA targets of mdv1-
miR-M4-5 and identiﬁed the latent TGF-β binding protein 1 (LTBP1) as a critical target for it. We found
that during MDV infection, down-regulation of LTBP1 expression by mdv1-miR-M4-5p led to a
signiﬁcant decrease of the secretion and activation of TGF-β1, with suppression of TGF-β signaling and
a signiﬁcant activation of expression of c-Myc, a well-known oncogene which is critical for virus-induced
tumorigenesis. Our ﬁndings reveal a novel and important mechanism of how mdv1-miR-M4-5p
potentially contributes to MDV-induced tumorigenesis.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
MicroRNAs (miRNAs) are a class of small, 22–24 nt-long, non-
coding RNAs (ncRNAs) that play important biological roles by the
regulation of gene expression post-transcriptionally (Bartel, 2004).
In the last decade, a large numbers of miRNAs had been identiﬁed
in diverse virus families, in particular in herpes viruses (Kozomara
and Grifﬁths-Jones, 2011; Kincaid and Sullivan, 2012). Previous
research on herpes virus-encoded miRNAs had demonstrated their
potential contributions to the control of latency/lytic activity,
immune evasion, cell survival, proliferation, and oncogenic cap-
abilities of these viruses (Boss et al., 2009). Marek's disease virus
(MDV) is an avian pathogenic alpha-herpes virus (Davison et al.,
2009), which has a double-stranded DNA genomic structure similar
to Herpes simplex virus (HSV, an alpha-herpes virus) but infects
lymphocytes and behaves biologically more like Epstein–Barr virus
(EBV, a gamma-herpes virus), particularly with its ability to induce
T-cell lymphoma (Ross, 1999). All three serotypes of MDV, MDV-1
(Gallid herpesvirus 2, GaHV2), MDV-2 (Gallid herpesvirus 3, GaHV3)
and herpesvirus of turkeys (HVT) (Meleagrid herpesvirus 1, MeHV1),
encode miRNAs in the long or short repeat (RL/RS) regions of their
genomes (Burnside et al., 2006; Yao et al., 2007, 2008, 2009;
Waidner et al., 2009). Although MDV-encoded miRNAs do not show
sequence conservation their highly conserved genomic location in
repeat regions implies that they may have speciﬁc functions.
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In MDV-1 genomes, the viral miRNAs are concentrated in three
gene clusters, namely the Meq-cluster, the mid-cluster, and the
LAT-cluster (Luo et al., 2010), with their transcription driven by
different promoters (Stik et al., 2010; Coupeau et al., 2012). Most of
the MDV-1 miRNAs are expressed at higher levels in splenic
tumors and virally-transformed T-lymphoma cell lines than in
virus-infected chicken embryo ﬁbroblast (CEF) (Burnside et al.,
2006; Yao et al., 2008). However, the in vivo expression proﬁles of
these miRNAs during different phases of the developing disease
suggest that they may have different regulatory roles in MD
pathogenesis (Luo et al., 2011). Although among oncogenic MDV-
1 strains of differing virulence the sequences of miRNA are highly
conserved, the Meq-clustered miRNAs are expressed at higher
levels in lymphomas produced by very virulent plus (vvþ) MDV
than those produced by a very virulent (vv) MDV strain, whereas
the LAT-clustered miRNAs expression is equal (Morgan et al.,
2008), implying that the Meq-clustered miRNAs may have a
signiﬁcant role in MDV virulence and oncogenesis.
The miRNA mdv1-miR-M4-5p, located in the Meq-cluster, is
one of the highest expressed MDV-1 miRNAs (Burnside et al.,
2006; Yao et al., 2008; Luo et al., 2011). It has been characterized
as a virus-encoded functional analog of eukaryotic cellular miR-
155 (Zhao et al., 2009) which speciﬁcally inhibits the translation of
viral proteins involved in the cleavage/packaging of herpesvirus
DNA (Muylkens et al., 2010). Since miR-155 is a host-encoded
multifunctional miRNA associated with several cancers and
regarded as an oncogene (Tam and Dahlberg, 2006; Faraoni
et al., 2009; Tili et al., 2009; Higgs and Slack, 2013; Kong et al.,
2014), mdv1-miR-M4-5p was hypothesized to play a potential role
in MDV oncogenesis. Recent studies have demonstrated a direct
critical involvement of mdv1-miR-M4-5p in the MD lymphoma-
genesis. The deletion of mdv1-miR-M4-5p from the viral genome
of the virulent (v) MDV strain pRB-1B5 abolished the oncogenicity
of the virus (Zhao et al., 2011) whereas for vvMDV strain GX0101,
compared to the parent virus, mortality of the mutant was
reduced from 100% to 18%, coupled with the gross tumor incidence
reduction from 28% to 22% (Yu et al., 2014). However, the under-
lying mechanism remained unclear. Here, using both bioinfor-
matics and experimental approaches, we have identiﬁed the host
mRNA targets and the associated signaling pathway regulated by
mdv1-miR-M4-5p during MDV infection and which begins to
uncover the mechanism of tumor induction in this virus.
Results
Candidate mRNA targets of mdv1-miR-M4-5p predicted
by bioinformatics method
A total of 12 candidate genes, as listed in Table S1, were obtained
utilizing ‘RNAhybrid’ from 189 host genes that are down-regulated
during the development of MDV infection in chickens or cell lines
(Haq et al., 2010; Parvizi et al., 2010; Kunec, 2013). While most of
the genes contain potential binding sites in the protein coding
sequence (CDS), three genes with predicted mdv1-miR-M4-5p
binding sites in the 30-UTRs, including LTBP1, chemokine (C-C motif)
receptor 7 (CCR7), and matrix metalloproteinase-13 (MMP-13). As
biological miRNA binding sites are primarily located in the 30-UTRs
of target mRNAs we focused on these three genes in the following
investigations.
Direct interactions between mdv1-miR-M4-5p and the 30-UTRs
of three candidate targets
To indicate whether mdv1-miR-M4-5p directly binds to the
30-UTRs of LTBP1, CCR7 and MMP-13, we performed site-directed
dual luciferase reporter assay (DLRA). For the ﬁrst round of DLRA
analysis, the vector expressing mdv1-miR-M4-5p (pcDNA6.
2-mdv1-miR-M4-5p) was co-transfected in the 293T cells with
psiCHECK-2 derived reporter vectors containing the 30-UTRs of
LTBP1, CCR7 and MMP-13 respectively, and then the relative
luciferase activities were calculated as indicated. As demonstrated
in Fig. 1a, all three 30-UTR reporters were signiﬁcantly repressed by
mdv1-miR-M4-5p, compared to the negative control miR-neg
(po0.01). To ensure that the down-regulation of targets by
mdv1-miR-M4-5p is seed sequence dependent, a speciﬁc mutant
vector of pcDNA6.2-mut-mdv1-miR-M4-5p, as shown on the left
side in Fig. 1 b–d, was constructed. Then, the second round of
DLRA analysis were performed and demonstrated that when the
seed sequence of mdv1-miR-M4-5p was mutated (mut-mdv
1-miR-M4-5p), the repression effect on reporters was lost
(Fig. 1b–d, black columns). To conﬁrm that the repression by
mdv1-miR-M4-5p on the 30-UTR reporters speciﬁcally depended
on the predicated binding sites, we further generated mutant
30-UTR reporters (mut-LTBP1-30-UTR, mut-CCR7-30-UTR and mut-
MMP13-30-UTR) and performed reporter assays again as above. As
expected, all mutant sites lost their response to mdv1-miR-M4-5p
(Fig. 1 b–d, gray columns), indicating the speciﬁcity of the repression.
mdv1-miR-M4-5p down-regulates the mRNA level of target gene
LTBP1 in the infected cells
The qRT-PCR analysis showed that, as demonstrated in Fig. 2a,
over-expression of mdv1-miR-M4-5p in CEFs signiﬁcantly reduced
the mRNA expressions of all the three candidate genes at 24 and
48 hpi (hour post-infection), but mutant mdv1-miR-M4-5p did
not. Subsequently, the intracellular miRNA/mRNA target interac-
tions were examined by an MDV de novo infection of CEFs using
the parental virus GX0101 or its mutant GXΔmiR-M4, in which the
mdv1-miR-M4-5p had been previously deleted from the viral
genome (Yu et al., 2014). Post-infection, the characteristic MDV
plaques were visible but very small at 48 hpi, enlarged and spread
rapidly to adjacent cells at 72 and 96 hpi, and then the cell cultures
were collected for subsequent experiments. As demonstrated in
Fig. 2b, the mRNA expression of LTBP1 was signiﬁcantly up-
regulated in GXΔmiR-M4-infected CEFs at 72 and 96 hpi (po0.01),
compared to that in GX0101-infected CEFs. In contrast, a similar
effect on the CCR7 andMMP13 genes was not observed. These results
suggest that LTBP1 is a biological target of mdv1-miR-M4-5p.
mdv1-miR-M4-5p suppressed the TGF-β signaling of infected cells
LTBPs have been shown to participate and regulate every step
in TGF-β's biology – from its folding and secretion, through its
localization, to its ﬁnal activation (Miyazono et al., 1991; Shi and
Massague,2003; Annes et al., 2004; Rifkin, 2005; Yoshinaga et al.,
2008; Buscemi et al., 2011). We ﬁrst analyzed the secretion of TGF-
β in cells infected with MDV by ELISA. Compared to uninfected
CEFs, the concentration of secreted TGF-β1 in the supernatants of
GX0101-infected CEFs is gradually decreased, while in GXΔmiR-
M4-infected cells it steadily increases (Fig. 3a). The difference in
the levels of secreted TGF-β1 between GX0101 and GXΔmiR-M4-
infected groups were signiﬁcant (po0.01), with values of 241.96
714.27 ng/ml vs 288.7279.92 ng/ml and 208.52717.53 ng/ml vs
285.4679.40 ng/ml at 96 and 120 hpi, respectively. In contrast, no
obvious change in the levels of intracellular TGF-β1 in MDV-
infected cells was observed (Fig. 3b), suggesting that mdv1-miR-
M4-5p reduces the secretion of TGF-β1 of infected cells.
Next, we analyzed the expression of a group of 84 genes
involved in the TGF-β pathway by TGF-β/BMP Signaling Pathway
PCR Array. The heat maps of PCR array analysis are demonstrated
in Fig. 4 and an overall gene expression proﬁles are listed in
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Fig. 1. Dual luciferase reporter assay (DLRA). (A) The ﬁrst round of DLRA for primary analysis of the interactions between mdv1-miR-M4-5p and 30-UTRs of mRNA targets.
(B– D) The second round of DLRA for conﬁrming the interactions between mdv1-miR-M4-5p and 30-UTRs of mRNA targets. The seed sequence of miRNA or binding sites of
30-UTRs (in blue) and corresponding mutants (underlined) are shown on the left side. 30-UTRs or the seed mutants (mut) of three genes, LTBP1, CCR7 and MMP13, were
cloned into psiCHECK-2 vector and then 293T cells were co-transfected with the reporter construct with plasmid expressing mdv1-miR-M4-5p, mut-mdv1-miR-M4-5p or
miR-neg. Fireﬂy and Renilla luciferase activities were measured consecutively with the dual luciferase reporter system (Promega). Reporter activities were standardized by
determining Renilla–ﬁreﬂy luminescence ratios. For each luciferase assay, relative luciferase activity was normalized with respect to pcDNA6.2-miR-neg vector. Error bars are
derived from three independent replicates. The signiﬁcant differences (po0.01 or po0.05) are indicated as double or single stars, respectively.
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Table S2. In GX0101 infected CEFs compared to GXΔmiR-M4-
infected CEFs, by 96 hpi, 15 genes were signiﬁcantly up-regulated
and 3 genes were down-regulated (Table 1). However, distinct
from the in vitro infections, more different gene expressions were
happened in MDV-challenged birds. As shown in Table 2, 22 up-
regulated genes and 4 down-regulated genes were ﬁrst observed
in the spleens of chickens that were infected with GX0101 at
30 dpi (days post infection), compared to GXΔmiR-M4-challenged
birds. But by 60 dpi, among the 22 genes (Nos. 1–22) up-regulated
at 30 dpi, 8 genes (Nos. 1–8) were further signiﬁcantly up-
regulated, 8 genes (Nos. 9–16) were unchanged whereas 6 genes
(Nos. 17–22) were conversely down-regulated. In addition, a total
of 28 genes (Nos. 23–50) were signiﬁcantly down-regulated in the
spleens of GX0101-challenged chickens (Table 2). Combining the
in vitro and in vivo results, 8 genes were signiﬁcantly up-regulated
and 3 genes were signiﬁcantly down-regulated in both, suggesting
that these 11 genes were most probably regulated by mdv1-miR-
M4-5p. Notably the signiﬁcantly down-regulated gene LTBP1 was
among the 3 genes down-regulated by mdv1-miR-M4-5p. In
addition, the cyclin-dependent kinase inhibitor 2B (CDKN2B), a
TGF-β induced cell cycle regulator, was also signiﬁcantly down-
regulated. In contrast, c-myc, a well-known oncogene, was the
most signiﬁcantly up-regulated gene both in vitro and in vivo.
Although the mechanism is not clear, several genes including the
transforming growth factor beta receptor III (TGFBR3), SMAD
family member 7 (SMAD7), TGFB-induced factor homeobox 1
(TGIF1), FBJ murine osteosarcoma viral oncogene homolog (FOS),
growth differentiation factor 7 (GDF7), follistatin (FST), and Throm-
bospondin 2 (THBS2), were also signiﬁcantly up-regulated by mdv1-
miR-M4-5p. These data indicate that mdv1-miR-M4-5p may pro-
mote tumorigenesis by interfering with TGF-β signaling.
mdv1-miR-M4-5p activates the expression of c-Myc protein during
MDV infection
It has been shown that c-Myc is a downstream target of TGF-β
signaling and that it is directly repressed by SMAD3 protein (Yagi
et al., 2002; Frederick et al., 2004). So we examined the expression
of c-Myc protein in MDV-infected cells. Signiﬁcant up-regulation
of c-Myc protein accompanied with obvious down-regulation of
Fig. 2. qRT-PCR analysis of the expression of mRNA target genes and mdv1-miR-M4-5p in CEFs over-expressed miRNAs (A) or infected with MDVs (B). miRNA OE, miRNA
over-expressed. The average mRNA expression levels for the corresponding genes from mock controls were set at 1. Error bars are derived from three replicates. The
signiﬁcant differences (po0.01 or po0.05) are indicated as double or single stars, respectively.
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LTBP1, was observed in both of the livers and spleens of GX0101-
challenged birds by IHA at 60 dpi (Fig. 5 and Fig. S1). However, in
mock controls and GXΔmiR-M4-challenged birds, the LTBP1 pro-
tein was normally expressed and the c-Myc was not activated.
Simultaneously localization of p-SMAD3, in the nucleus, reﬂecting
the activity of TGF-β signaling, was also down-regulated in GX0101
rather than GXΔmiR-M4-challenged birds or mock controls (Fig. 5
and Fig. S1). Western blot analysis was performed to further
examine the relative expression of mdv1-miR-M4-5p, LTBP1 and
c-Myc proteins in CEFs over-expressing mdv1-miR-M4-5p or
transfected with LTBP1-speciﬁc siRNAs. Compared to controls,
LTBP1 was signiﬁcantly down-regulated whereas the expression
of c-Myc was apparently up-regulated in mdv1-miR-M4-5p over-
expressed cells, parallel to that in MDV-infected CEFs (Fig. 6a and
b). Notably, a similar protein expression pattern was observed in
LTBP1-silenced CEFs and negative controls (Fig. 6c). These data
suggest that the increase of c-Myc protein is possibly due to the
down-regulation of LTBP1 by mdv1-miR-M4-5p.
Targeting of LTBP1 by mdv1-miR-M4-5p activates cellular
proliferation
Compared to the mock transfected cell or negative control, the
CEF cell viability/proliferation was signiﬁcantly increased follow-
ing infection by GX0101 or transfection with mdv1-miR-M4-5p,
but apoptosis was unaffected (Fig. 7). Importantly, a very similar
phenotype was observed in the cells transfected with LTBP
1-speciﬁc siRNAs. This data strongly indicates that mdv1-miR-
M4-5p activates cellular proliferation via down-regulation of
LTBP1. c-Myc is a prominent activator of abnormal proliferation
in the development of various tumors and our data suggests that
the de-repression of c-Myc may be a primary factor in the effect of
mdv1-miR-M4-5p on cellular proliferation. In summary we con-
clude that mdv1-miR-M4-5p by targeting LTBP1 suppresses the
TGF-β pathway and de-represses the oncogene c-myc during
MDV-induced tumorigenesis.
Discussion
Mdv1-miR-M4-5p is a virus-encoded analog of miR-155 that
has been shown to play a critical role in the induction of MD
lymphomas (Zhao et al., 2009, 2011; Yu et al., 2014). However due
to ignorance of the biological targets of viral miRNAs, the mechan-
ism by which mdv1-miR-M4-5p assisted in MDV-induced
tumorigenesis remained unclear. Here we have shown that the
mdv1-miR-M4-5p directly targets the LTBP1 gene and thereby
down-regulates TGF-β signaling resulting in a signiﬁcant activation
of the c-myc gene, a key oncogene implicated in various virus-
induced tumors. Because mdv1-miR-M4-5p and miR-K12-11
encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) pos-
sess the same seed sequence as miR-155 (Gottwein et al., 2007;
Skalsky et al., 2007; Zhao et al., 2009), they are expected to regulate
a group of conserved mRNA targets. Nine conserved targets,
including CSNK1A1, RPS6KA3, WEE1, RORA, MYB, C1orf103, LATS2,
NR and MAP recognized by mdv1-miR-M4-5p, have been recently
reported as mRNA targets of MDV-1 miRNAs (Parnas et al., 2014). In
addition, the mRNA repertoire for miR-K12-11 has also been reported
(Gottwein et al., 2011; Haecker et al., 2012). Evolutionary analysis of
the binding site of mdv1-miR-M4-5p on 30-UTR of LTBP1 shows that
there is a non-canonical but low-free-energy match between human
miR-155 and human LTBP1 (Fig. S2). However whether this regula-
tory relationship is conserved across amniotic animals will need to be
determined in the future. Our ﬁndings revealed a novel mechanism,
as proposed in Fig. 8, to understand how mdv1-miR-M4-5p poten-
tially contributes to MDV-induced tumorigenesis.
Consistent with the presently suggested mechanism miR-155
has also been shown to suppress TGF-β signaling by directly
targeting the SMAD family, including the SMAD2 and SMAD5
(Louaﬁ et al., 2010; Rai et al., 2010). Interestingly, other viral miR-
155 analogs have also been shown to inhibit TGF-β signaling. For
example, KSHV-encoded miR-K12-11 attenuates TGF-β signaling
through suppression of SMAD5 (Liu et al., 2012) and thrombos-
pondin 1 (THBS1) (Samols et al., 2007), a strong tumor suppressor
and anti-angiogenic factor which exerts its anti-angiogenic effect
in part by activating the latent form of TGF-β. EBV, one of the
human oncogenic herpesviruses, has no viral miR-155 analog
encoded in its genome while the host cellular miR-155 is induced
in B cells by its oncogenic latency gene expression program. The
miR-155 inhibits the bone morphogenetic protein (BMP)-induced
EBV reactivation and the antitumor effects of BMP signaling by
controlling BMP-mediated cellular processes (Yin et al., 2010).
These ﬁndings suggest that miR-155 and its viral analogs may
primarily contribute to virus-induced oncogenesis by disregulating
the TGF-β/BMP signaling pathways.
The TGF-β super family involves more than 30 members,
including the TGF-β proteins (TGF-βs) and BMP proteins (BMPs),
among which TGF-βs are prominent regulatory cytokines secreted
by all immune cells, particularly by macrophages. Thus, TGF-β has
immunological regulatory effects and inactivation of this pathway
allowing the tumor to escape the growth inhibitory and pro-
apoptotic activities of TGF-β (Moustakas et al., 2002; Massagué,
2008; Heldin et al., 2009; Katz et al., 2013). Whether the TGF-β
signaling pathway is widely involved in virus infection and oncogen-
esis is undetermined. Interestingly, mdv1-miR-M3-5p, another viral
miRNA encoded by oncogenic MDVs, has also been suggested to
contribute to the induction of MD lymphomas by targeting SMAD2 of
the TGF-β signaling pathway (Xu et al., 2011). Previous studies have
shown that c-Myc is a downstream target of TGF-β signaling and that
it is directly repressed by SMAD protein complexes (Seoane et al.,
Fig. 3. ELISA analysis of the expressions of extracellular (A) and intracellular
(B) TGF-β1 in MDV-infected CEFs. For each group, the concentrations of TGF-β1
were measured in triplicate at any time point post-infection. The double stars
indicate signiﬁcant difference (po0.01).
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2004; Gomis et al., 2006). So it may be an another mechanism of MDV
to trigger c-Myc induction and to explain the western blot data, as
shown in Fig. 6, siRNA at 24 h post-transfection nearly degraded
LTBP1, c-Myc is just being detectable, while during virus infection at
72 hpi LTBP1 is only reduced by about 50%, yet c-Myc is already fully
induced. Furthermore, a recent study has shown that the variants of
KSHV miR-K10 directly inhibit TGF-β signaling by targeting TGFBR2 to
promote cell survival (Lei et al., 2012), together with several other viral
miRNAs such as miR-K12-1, miR-K12-3-3p and miR-K12-6-3p,
decrease the TGF-β signaling indirectly by targeting the protein THBS1
(Yin et al., 2010). All these studies indicate that the TGF-β signaling
pathway may be a common target of oncogenic viruses.
Previously only the MEQ protein of MDV had been character-
ized as a major oncoprotein (Nair and Kung, 2004) but little was
known as to how it fulﬁlled this role in MDV oncogenesis. In a
recent study (Stik et al., 2013), MEQ has been found capable
of binding to the promoter of gga-miR-21, a cellular onco-miR of
Gallus gallus, activating its over-expression and so mediating MDV
lymphomagenesis, and indicating that host miRNAs may be recruited
in the viral induction of tumors. Unexpectedly, the oncogene meq is
also possibly self-regulated by viral miRNAs, such as mdv1-miR-M5-
3p, mdv1-miR-M7-5p, mdv1-miR-M11-5p and mdv1-miR-M12-3p,
during MDV infection (recently conﬁrmed in our laboratory-in pre-
paration). It seems that a complicated regulatory network mediated by
miRNAs is present to control both the oncoprotein and tumorigenesis-
associated signaling pathways.
Whether and how viral miRNAs might co-operate with viral
protein genes is currently poorly understood. Interestingly, pre-
vious studies had shown that the MEQ protein can form hetero-
dimers with c-Myc (Qian et al., 1996; Osterrieder et al., 2006), and
the latter directly activates the telomerase reverse transcriptase
(TERT) (Wu et al., 1999). Therefore, our ﬁndings further support a
Fig. 4. Heat maps of the PCR array analysis of TGF-β signaling pathway. The expression levels of the 84 genes of TGF-β signaling pathway in MDV-infected CEFs (A) or spleens of
MDV-challenged birds (B) were quantiﬁed by real-time PCR with SYBR Green Master Mix. The heat map shows fold expression differences, which were calculated from PCR cycle
thresholds (Ct) analyzed through the QIAGEN Web page. Five endogenous controls, β-actin (ACTB), hexose-6-phosphate dehydrogenase (H6PD), hydroxymethylbilane synthase
(HMBS), ribosomal protein L4 (RPL4), and ubiquitin C (UBC) were used for normalization. hpi, hours post-infection; dpi, days post-infection; mock, uninfected CEFs or spleens of
birds; wt, GX0101; mut, GXΔmiR-M4.
J.-Q. Chi et al. / Virology 476 (2015) 72–84 77
role of mdv1-miR-M4-5p in MD development, as shown in Fig. 8.
According to this model, mdv1-miR-M4-5p acts as an important
onco-miR which activates the expression of c-Myc in host cells by
targeting LTBP1 and so suppressing the TGF-β signaling. This induced
de-repression of c-Myc expression will lead to an increase in cellular
metabolism, including protein and nucleotide synthesis (Meyer and
Penn, 2008). This could be of an advantage to the virus, enhancing
the production of new virus particles (Yu et al., 2014) and the
oncogenic side-effect on the host would in addition provide more
cells for infection (Xu et al., 2011). Thus the appearance of these
miRNAs in the MDV genome could have a strong selective advantage.
Materials and methods
Viruses and cells
A BAC-derived virus based on the vvMDV GX0101, retaining the
original pathogenicity (Sun et al., 2009), was used as the parental
virus for further genetic manipulation. GXΔmiR-M4, with mdv1-
miR-M4 deleted from the viral genome of GX0101, was rescued by
transfection of the BAC DNA into CEF cultures (Yu et al., 2014).
Primary CEF cultures were prepared from 9-day-old embryonated
eggs (Jinan SPF Egg & Poultry Co., China) for virus propagation and
the plaque forming units (PFUs) of MDVs were measured as
described previously (Luo et al., 2011; Yu et al., 2013). 293 T cells
(American Type Culture Collection, Manassas, VA) were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS, Gibco). All cells were maintained at
37 1C in a 5% CO2 incubator.
Bioinformatics prediction
All the reports on the transcriptome and proteome proﬁling of
host responses to MDV infection in chicken organs or cell lines
(Haq et al., 2010; Parvizi et al., 2010; Kunec, 2013) were collected
and analyzed, and then all the genes down-regulated during MDV
infection were used for the prediction of mRNA targets, utilizing
the miRNA target prediction bio-software ‘RNAhybrid’ (Rehmsmeier
et al., 2004). For target screening, the criteria are set as follows: a
perfect Watson–Crick match between miRNA and target at miRNA
positions 2–8 and disallowance of G:U pairs in the ‘seed’.
Vector construction
A series of vectors containing miRNA precursor or chicken
entire 30-UTR were ﬁrst constructed for the primary screening of
host mRNA targets. MDV genomic DNAs and CEF cellular RNAs
were extracted from virus-infected or mock infected CEFs as
described previously (Yu et al., 2014). The precursor gene of
mdv1-miR-M4-5p was ampliﬁed using primer pair #1 (Table S3),
and then cloned into the Xho I and EcoR I sites of plasmid
pcDNA6.2 (Invitrogen) to construct the vector pcDNA6.2-mdv1-
miR-M4-5p. The reverse transcription PCR (RT-PCR) was per-
formed to amplify the wild-type 30-UTRs of host mRNA targets
using primer pairs #2–#4 (Table S3). The PCR products were
puriﬁed and cloned into the Not I and Xho I sites of psiCHECK-2
(Promega) to construct three vectors, namely psiCHECK-2-LTBP1-
30-UTR, psiCHECK-2-CCR7-30-UTR and psiCHECK-2-MMP13-30–
UTR, respectively. Mutants of the miRNA precursor and chicken
partial 30-UTR were obtained by annealing the oligonucleotides
(primer pairs #5–#8, Table S3) and then similarly cloned into
psiCHECK-2 to construct the corresponding vectors named as
pcDNA6.2-mut-mdv1-miR-M4-5p, psiCHECK-2-mut-LTBP1-30-UTR,
psiCHECK-2-mut-CCR7-30-UTR and psiCHECK-2-mut-MMP13-30-UTR,
respectively. All the DNA primers and oligonucleotides used in this
study were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China).
Dual luciferase reporter assay
The miRNA–mRNA target interactions were determined by dual
luciferase reporter assay (DLRA). Brieﬂy, the mixed plasmids, each
at 100 ng per well, of the vectors of psiCHECK-2 vector expressing
each 30-UTR or their mutants plus vectors pcDNA6.2-mdv1-miR-
M4-5p, pcDNA6.2-mut-mdv1-miR-M4-5p, or pcDNA6.2-miR-neg,
were co-transfected into the conﬂuent 293 T cells in 96-well plates
using Lipofectamine 2000 according to the manufacturer's proto-
col (Invitrogen). Cell cultures were maintained in a 5% CO2
incubator at 37 1C for 48 h and then analyzed using the Dual-
luciferase reporter system (Promega, #E1910). The growth med-
ium was removed and washed twice with phosphate buffered
saline (PBS, pH 7.4), and then 20 ml of 1 passive lysis buffer (PLB)
was added into each culture well and set aside for 15 min at room
temperature. Subsequently, 100 ml of Luciferase Assay Buffer II
(LAR II) was added per well for the measurement of the ﬁreﬂy
luciferase activity, followed by dispensing 100 ml of Stop & Glos
Reagent to determine the Renilla luciferase activity. Both ﬁreﬂy
luciferase activity and Renilla luciferase activity were measured by
using a GloMaxTM 96 Microplate Luminometer (Promega, Madi-
son, WI). Each experiment was repeated independently three
times with the determinations made in triplicate and then the
data were calculated as means (M)7standard deviations (SD)
utilizing the software GraphPad Prism (version 5.0).
Over-expression of miRNA in CEFs
To investigate whether mdv1-miR-M4-5p down-regulates tar-
get gene expression at the transcriptional level, the conﬂuent CEF
monolayers in 6-well plates were transfected with vector plasmids
pcDNA6.2-mdv1-miR-M4-5p or pcDNA6.2-mut-mdv1-miR-M4-5p,
and then maintained in a 5% CO2 incubator at 37 1C, respectively. The
ratio of transfection reagent:plasmid is 1:1, using the X-tremeGENE
Table 1
Differential gene expressions in the TGF-β/BMP signaling pathway in MDV strains
GX0101 or GXΔmiR-M4-infected CEFs.
No. Genec Fold changea,b
GX0101/mock GXΔmiR-M4/mock GX0101/GXΔmiR-M4
72 hpi 96 hpi 72 hpi 96 hpi 72 hpi 96 hpi
1 MYC 2.77 3.08 0.58 0.22 4.78 14.00
2 TGFBR3 1.01 0.25 0.32 0.03 3.12 8.83
3 COMP 2.13 1.30 0.86 0.16 2.48 8.13
4 THBS4 0.72 0.58 0.31 0.08 2.32 7.25
5 IGF1 1.37 1.89 0.85 0.35 1.61 5.40
6 SMAD7 2.33 3.62 1.57 0.78 1.48 4.64
7 TGIF1 2.30 2.52 0.49 0.56 4.69 4.50
8 GSC 0.56 0.34 0.36 0.08 1.57 4.00
9 TNFSF10 2.70 1.23 1.18 0.34 2.29 3.62
10 GDF2 0.20 0.90 0.38 0.26 0.53 3.42
11 FOS 0.55 0.46 0.28 0.15 1.94 3.09
12 GDF7 0.57 0.90 0.61 0.29 0.94 3.08
13 FST 2.67 5.88 1.48 2.26 1.80 2.60
14 THBS2 0.37 0.22 0.17 0.09 2.17 2.43
15 ENG 3.58 2.15 1.52 0.91 2.36 2.36
16 PLAU 1.62 1.49 3.00 3.12 0.54 0.48
17 CDKN2B 0.53 0.74 3.20 3.99 0.17 0.19
18 LTBP1 0.65 0.99 2.03 6.64 0.32 0.15
a Fold change ≧ 2.0 or ≦ 0.5 indicates the signiﬁcant (po0.05) up-regulation
and down-regulation of gene expression, respectively.
b The signiﬁcant (po0.05) differently expressed genes in GX0101-infected
CEFs, compared to GX△miR-M4 group, are shown in bold.
c Abbreviations for chicken genes, of which the full names and corresponding
functions are listed in Table S4.
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according to the manufacturer's protocol (Roche). The transfection
efﬁciency was evaluated by detecting the Emerald green ﬂuorescent
protein (EmGFP) of vectors under ﬂuorescence microscopy (Leica,
Germany). At 24 and 48 h post-transfection (hpt), cell cultures were
collected for subsequent qRT-PCR and/or western blot analysis.
Quantitative real-time PCR
A quantitative real-time PCR (qRT-PCR) was performed to
analyze the transcription levels of target mRNAs in CEFs. Brieﬂy,
total RNAs were extracted from the CEFs infected with MDVs or
transfected with mdv1-miR-M4-5p, using the TRIzol reagent accord-
ing to the manufacturer's instructions (Invitrogen). To obtain cDNA,
2 μg of total RNAs, in 40 ml reverse-transcription reagent, were
reverse transcribed using the PrimeScriptTM RT reagent Kit with
gDNA Eraser according to the manufacturer's protocol (Takara). The
primer pairs speciﬁc for LTBP1, chemokine (C-C motif) receptor 7
(CCR7), matrix metalloproteinase 13 (MMP13) and internal control
β-actin gene are listed in Table S3 (primer pairs #9–#12), and the
7500 Fast Real-Time PCR Systems (Applied Biosystems, Life Technol-
ogies, USA) were used for qRT-PCR ampliﬁcations. The total 20 ml PCR
reaction includes 1 μl of cDNA templates, 10 mM of each speciﬁc
primer, and 2 SYBR Premix Ex TaqTM (TaKaRa). The reaction
conditions were set as follows:- 95 1C for 3 min, and 40 cycles of
95 1C for 15 s followed by 60 1C for 1 min. Relative quantiﬁcation of
the target gene expression was calculated with the 2△△Ct method.
Table 2
Differential gene expressions in the TGF-β/BMP signaling pathway in spleens from MDV-challenged birds.
No. Genec Fold changea,b
GX0101/mock GXΔmiR-M4/mock GX0101/GXΔmiR-M4
30 dpi 60 dpi 30 dpi 60 dpi 30 dpi 60 dpi
1 MYC 2.37 3.28 0.79 0.61 2.99 5.37
2 FST 4.59 5.67 0.97 1.14 4.73 4.95
3 SMAD7 2.14 2.52 0.73 0.61 2.94 4.09
4 FOS 8.60 6.01 3.30 2.13 2.60 2.82
5 TGIF1 3.33 3.01 1.22 0.82 2.73 3.70
6 TGFBR3 2.77 2.90 1.19 1.09 2.31 2.66
7 THBS2 1.09 1.05 0.63 0.40 1.73 2.59
8 GDF7 1.86 6.30 1.12 2.62 1.65 2.40
9 SOX4 3.31 0.62 0.83 0.65 3.99 0.96
10 GADD45B 2.60 0.84 0.79 0.80 3.31 1.05
11 BMP7 3.34 0.35 1.18 0.62 2.82 0.57
12 SMAD3 1.76 0.69 0.74 0.88 2.37 0.77
13 BMPR1A 2.26 0.27 0.95 0.49 2.37 0.56
14 SMAD2 1.67 0.66 0.74 0.72 2.26 0.92
15 TGFBR1 1.69 0.45 0.83 0.54 2.05 0.83
16 SMURF1 1.48 0.43 0.73 0.54 2.02 0.80
17 BMP2 4.31 0.22 0.87 0.52 4.96 0.42
18 MECOM 3.51 0.99 0.73 0.21 4.78 0.47
19 ID1 1.19 0.26 0.28 0.70 4.25 0.38
20 SMAD6 2.43 0.09 0.62 0.45 3.88 0.21
21 TGFB2 1.75 0.23 0.63 0.64 2.76 0.35
22 TGFBRAP1 2.23 0.01 0.93 0.75 2.39 0.01
23 BAMBI 1.19 0.22 0.86 0.46 1.39 0.48
24 AMH 0.42 0.19 0.66 0.41 0.63 0.47
25 ATF4 0.71 0.23 0.82 0.51 0.86 0.46
26 RBL1 0.199 0.35 0.64 0.62 0.31 0.46
27 NOG 1.67 2.06 1.86 4.95 0.90 0.42
28 INHA 1.12 2.62 1.86 6.30 0.60 0.42
29 NODAL 1.12 2.62 1.86 6.30 0.60 0.42
30 GSC 1.12 2.62 1.86 6.30 0.60 0.42
31 BMPR1B 1.12 0.63 1.86 1.52 0.60 0.42
32 BMP3 1.24 2.62 1.86 6.03 0.60 0.42
33 THBS4 1.79 0.42 1.717 1.02 1.04 0.41
34 GDF5 1.24 2.62 1.86 6.30 0.60 0.41
35 GDF2 1.12 1.89 1.86 4.55 0.60 0.41
36 CDKN2B 1.15 0.22 2.56 0.53 0.44 0.41
37 TGFB3 1.38 0.42 0.86 1.07 1.60 0.40
38 ID2 1.13 0.12 0.72 0.32 1.58 0.38
39 IL-6 1.90 0.21 1.86 0.55 1.03 0.38
40 INHBA 0.51 0.26 1.02 0.73 0.49 0.36
41 LTBP1 0.57 0.54 1.07 1.61 0.54 0.33
42 HIPK2 1.13 0.26 1.03 0.82 1.10 0.31
43 PLAU 0.22 0.14 0.43 0.44 0.51 0.31
44 IGF1 0.85 0.22 1.87 0.75 0.46 0.30
45 CREBBP 0.95 0.21 0.59 0.78 1.60 0.27
46 GDF3 0.91 0.24 1.64 0.90 0.55 0.26
47 INHBB 1.43 0.14 1.86 0.54 0.77 0.25
48 COL1A1 0.88 0.16 0.91 0.71 0.96 0.23
49 IGFBP3 1.97 0.18 1.01 0.81 1.95 0.22
50 CHRD 1.58 0.09 1.10 0.72 1.44 0.12
a Fold change ≧ 2.0 or ≦ 0.5 indicates the signiﬁcant (po0.05) up-regulation and down-regulation of gene expression, respectively.
b The signiﬁcant (po0.05) differently expressed genes in GX0101-challenged birds, compared to GX△miR-M4 group, are shown in bold.
c Abbreviations for chicken genes, of which the full names and corresponding functions are listed in Table S4.
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Fig. 5. Expressions of LTBP1, c-Myc and p-SMAD3 proteins in MDV-challenged chickens determined by immunohistochemistry assay (IHA). Liver tissues of birds infected
with MDVs at 60 dpi were sampled for the preparation of pathological sections and further IHA analysis. The sections were staining with hematoxylin and eosin (HE) and the
chicken β-actin protein serves as positive control for IHA analysis, of which the positive staining of detected proteins are shown by black arrows.
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While for the absolute quantiﬁcation of mdv1-miR-M4-5p by qRT-
PCR, 1 mg of total RNAs were used for poly(A) tailing and cDNA
synthesis using the NCodeTM VILOTM miRNA cDNA Synthesis Kit
(InvitrogmkAen, A11193-050), according to the manufacturer's pro-
tocol. PCR ampliﬁcation was set up in a 20 ml reaction containing 2 ml
of cDNA, 10 ml of SuperMix with Premixed ROX, 20 nM of universal
qPCR Primer (Invitrogen, A11193-051) and 200 nM of mdv1-miR-
M4-5p speciﬁc primer #13 (Table S3). Synthetic miRNA mdv1-miR-
M4-5p (Sangon Biotech Co., Ltd., Shanghai, China) was used as the
standard. Each reaction was performed in triplicate repeats and the
data were calculated as M7SD as described above.
Virus infection of CEFs with MDVs
The conﬂuent CEF monolayers in 6-well plates were infected
with the viruses GX0101 or GXΔmiR-M4, each at 100 PFUs per
well, and then maintained in DMEM medium supplemented with
1% FBS (Gibco) at 37 1C in a 5% CO2 incubator. Uninfected CEFs
were maintained in same conditions served as mocks. The experi-
ments were performed in triplicate independent repeats and at 72
and 96 hpi, the cell cultures were collected for subsequent qRT-
PCR, ELISA, and/or western blot analysis.
Animal experiments
The animal experiments with chickens were performed follow-
ing the protocols of the Ethical and Animal Welfare Committee of
Key Laboratory of Animal Immunology of the Ministry of Agricul-
ture of China, as previously reported in Yu et al. (2014) and utilizing
the same control groups. Brieﬂy, one-day-old white Leghorn SPF
chickens, were separately challenged with CEFs containing 2000
PFUs of GX0101 or GXΔmiR-M4 viruses by abdominal cavity inocu-
lation. At 30 and 60 dpi, three birds from the experimental groups
were randomly selected and humanely euthanized. Spleens were
collected for subsequent experiments, such as PCR array analysis,
pathological section preparation and immunohistochemistry
assay (IHA).
PCR array analysis
The chicken TGF-β/BMP Signaling Pathway PCR Array (QIAGEN,
#PAGG-035ZC-2) was used for analyzing the expressions of all of
the 84 genes in this pathway. Total RNAs of virus-infected CEFs
sampled from triplicate independent experiments or spleens from
three MDV-challenged birds collected as mentioned above were
extracted and puriﬁed with the RNeasy Mini Kit with on column
DNase treatment (QIAGEN, #74104). For each sample, a total of
5 mg RNAs were used for cDNA synthesis using the RT2 First Strand
Kit (QIAGEN, #330401) according to the manufacturer's protocol
Fig. 7. Determination of the cell viability (A) and apoptosis (B) of the CEFs infected with MDVs, over-expressed miRNAs or transfected with LTBP1-speciﬁc siRNAs. miRNA OE,
over-expression of miRNAs; RNAi, RNA interference. The uninfected or untransfected CEFs serve as mock controls. Error bars are derived from three independent replicates.
The signiﬁcant differences (po0.01 or po0.05) are indicated as double or single stars, respectively.
Fig. 6. Expressions of LTBP1 and c-Myc proteins in CEFs determined by the western
blot. Proteins from the extracellular matrix and/or cytoplasm of CEFs infected with
MDVs (A), over-expressed miRNAs (B) or transfected with LTBP1-speciﬁc siRNAs
(C), were extracted at different time points post-infection or post-transfection and
then subjected to western blot analysis. The uninfected or untransfected cells serve
as mock controls. miRNA OE, over-expression of miRNAs.
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and then PCR array analysis was performed. Brieﬂy, 1 mg of cDNA,
each containing equally mixed cDNA from triplicate samples,
was mixed with 1.35 ml RT2 SYBR Green ROX qPCR Mastermix
(QIAGEN, #330520) and dispensed into one PCR Array plate, and
then run on 7500 Fast Real-Time PCR Systems (Applied Biosys-
tems, Life Technologies, USA). The PCR cycling condition was set as
follows:95 1C for 10 min, 40 cycles of 95 1C for 15 s followed by
60 1C for 1 min. Gene expression differences were analyzed using
the corresponding web-based PCR software (QIAGEN).
Determination of TGF-β1 by ELISA
The chicken TGF-β1 ELISA Kit (Qayee-Bio, #ABIN1525195) was
used to determine the expression levels of TGF-β1 in CEFs. As
described above, the CEF cultures infected with MDVs were
collected at 72, 96 and 120 hpi and centrifuged for 20 min at
3000 rpm, and then the supernatants used for the determination
of secreted TGF-β1. The cell pellets were collected and diluted with
PBS (pH 7.4) to a concentration of 106 cells/ml, freeze/thawed
three times to release intracellular TGF-β1. Following centrifuga-
tion the supernatants were collected for the determination of
intracellular TGF-β1. All the experiments were performed in
triplicate independent repeats.
Gene silence of LTBP1 in CEFs
Small interfering RNAs (siRNAs) speciﬁc to LTBP1 gene were
designed and synthesized by GenePharma (Shanghai, China), and
then used for silencing the expression of LTBP1 in CEFs. Brieﬂy, CEF
monolayers reached a conﬂuency of about 70% in 24-well plates
were transfected with 50 nM siRNAs of LTBP1-2913 or siR-neg
(primer pairs#14 and 15, Table S3) combined with HiPerfect
Transfection Reagent (4.5 ml per well) (QIAGEN, #301704), accord-
ing to the handbook. Cells were collected at 24 and 48 hpt and
used for subsequent western blot analysis.
Western blot
For analyzing the expression of LTBP1 and c-Myc at the protein
level, protein was extracted from both the cytoplasm and extra-
cellular matrix of CEFs infected with MDVs, over-expressing mdv1-
miR-M4-5p or transfected with LTBP1-speciﬁc siRNAs. Uninfected
or untransfected cells are used as mock controls. Brieﬂy, the
collected CEF cultures were washed twice with PBS (pH 7.4) and
then lyzed with the Radioimmunoprecipitation assay (RIPA) lysis
buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS)
on ice. The cell lysates were centrifuged at 14,000 rpm for 10 min,
and the supernatants were collected as the cytoplasmic protein
while the insoluble pellet was collected for preparing the matrix
protein. The pellet was washed in PBS (pH 7.4) and then digested
with plasmin (0.1 U/ml) (Sigma, P1867-150UG) in serum-free
DMEM medium for 1 h. Proteins released by plasmin digestion
were concentrated by precipitation in 80% ethanol. After centrifu-
gation, the protein pellet was dissolved in non-reducing sample
buffer and stored at 20 1C for further experiments. Western blot
analysis was performed in a conventional way. The antibodies
against the chicken proteins LTBP1 (prepared in our lab, unpub-
lished data), c-Myc (Santa Cruz Biotechnology, INC, sc-42) or
β-actin (Abcam, ab8227) were used as primary antibodies while
the HRP-conjugated goat anti-mouse IgG (Biosynthesis Biotech-
nology Co., Ltd., bs-0296Gs) serves for the second antibody. Finally,
the membranes were washed and visualized on a photographic
ﬁlm (Kodak) using the ECL chemiluminescence system (Cell
Signaling Technology).
Immunohistochemistry assay
Spleens from MDV-challenged birds were collected, ﬁxed in
10% formalin and processed for embedding in parafﬁn. 5 mm thick
sections were prepared and stained with hematoxylin and eosin
(HE). After staining, tissue sections were examined for lesions
using a DM6000 light microscope (Leica, Germany). For IHA, serial
sections of spleen tissues were placed on clean microscope slides,
and then the expressions of LTBP1, c-Myc, p-SMAD3 and β-actin
proteins were determined using a microwave-based antigen
retrieval technique (Lan et al., 1995). The presently used primary
and secondary antibodies for LTBP1, c-MYC and β-actin were
identical to those which had been used for western blot analysis
and for p-SMAD3, the primary antibody was provided by Abcam
(ab51451). Immunostaining was visualized with 3,30-diaminoben-
zidine tetrahydrochloride/hydrogen peroxide as chromogen and
sections were counterstained with hematoxylin.
Fig. 8. Schematic for the role of MDV in promoting tumorigenesis. Both viral
miRNA and protein may together promote changes in the TGF-β signaling pathway
which could facilitate tumorigenesis in a normal cell. In normal cell metabolism (in
blue) the production of the metabolic promoter c-Myc is down-regulated by the
phosphorylated complex of SMAD2/3, produced by TGF-β1 ligand binding to its
receptor. Following MDV infection (in red, plus sequelae) and the production of the
viral miRNA mdv1-miR-M4-5p, the level of LTBP1, necessary for the conversion of
latent TGF-β1 to secreted active TGF-β1, is decreased. As a consequence, there is a
reduction in the active SMAD2/3 complex and so a release of the inhibition of the
c-Myc promoter, resulting in a rise in c-Myc transcription. Further the production of
viral protein MEQ allows the formation of complexes with c-Myc, increasing the
effects of c-Myc on cell metabolism, including protein and nucleotide synthesis,
thus increasing the chances for cellular transformation.
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Measurement of cell viability and apoptosis
A commercial cell counting Kit-8 (CCK-8) (Beyotime, China)
was used to assess the inﬂuence of mdv1-miR-M4-5p expression
on CEF proliferation activity. Brieﬂy, CEFs in 96-well plates infected
with MDVs, over-expressing mdv1-miR-M4-5p or LTBP1-speciﬁc
siRNAs were added with CCK-8 (10 ml each well) and incubated at
37 1C for 1 h, and then the absorbance at 450 nm was measured
using a iMarkTM Microplate Reader (BIO-RAD). For analyzing cell
apoptosis, the Caspase 3/7 activity was measured using the
Caspase-Glos 3/7 assay Kit (Promega) according to the manufac-
turer's instructions. Brieﬂy, the same batches of CEFs mentioned
above were lysed with Caspase-Glos 3/7 reagent (100 ml each
well) for 30 min and then the luminescence was measured by
BMG LABTECH (Omega).
Acknowledgments
This work was supported by grants of the National Natural
Science Foundation of China (No. 31372445), the Key Project of
NSFC-Guangdong Joint Fund (No. U1131005), and the Science-
Technology Foundation for Outstanding Young Scientists of Henan
Academy of Agricultural Sciences (No. 2013YQ28). The authors
gratefully acknowledge the critical review by Prof. Norman A.
Gregson (ION, UCL, London, UK).
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2014.11.027.
References
Annes, J.P., Chen, Y., Munger, J.S., Rifkin, D.B., 2004. Integrin alphaVbeta6-mediated
activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J.
Cell. Biol. 165, 723–734.
Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell
116, 281–297.
Boss, I.W., Plaisance, K.B., Renne, R., 2009. Role of virus-encoded microRNAs in
herpesvirus biology. Trends Microbiol. 17, 544–553.
Burnside, J., Bernberg, E., Anderson, A., Lu, C., Meyers, B.C., Green, P.J., Jain, N., Isaacs,
G., Morgan, R.W., 2006. Marek's disease virus encodes MicroRNAs that map to
meq and the latency-associated transcript. J. Virol. 80, 8778–8786.
Buscemi, L., Ramonet, D., Klingberg, F., Formey, A., Smith-Clerc, J., Meister, J.J., Hinz,
B., 2011. The single-molecule mechanics of the latent TGF-beta1 complex. Curr.
Biol. 21, 2046–2054.
Coupeau, D., Dambrine, G., Rasschaert, D., 2012. The kinetic expression analysis of
the cluster mdv1-mir-M9M4, genes meq and vIL-8 differs between the lytic
and latent phases of Marek's disease virus infection. J. Gen. Virol. 93,
1519–1529.
Davison, A.J., Eberle, R., Ehlers, B., Hayward, G.S., McGeoch, D.J., Minson, A.C., Pellett,
P.E., Roizman, B., Studdert, M.J., Thiry, E., 2009. The order Herpesvirales. Arch.
Virol. 154, 171–177.
Faraoni, I., Antonetti, F.R., Cardone, J., Bonmassar, E., 2009. miR-155 gene: a typical
multifunctional microRNA. Biochim. Biophys. Acta 1792, 497–505.
Frederick, JP., Liberati, NT., Waddell, DS., Shi, Y., Wang, XF., 2004. Transforming
growth factor beta-mediated transcriptional repression of c-myc is dependent
on direct binding of Smad3 to a novel repressive Smad binding element. Mol.
Cell. Biol. 24, 2546–2559.
Gomis, R.R., Alarcón, C., He, W., Wang, Q., Seoane, J., Lash, A., Massagué, J., 2006.
A FoxO-Smad synexpression group in human keratinocytes. Proc. Natl. Acad.
Sci. USA 103, 12747–12752.
Gottwein, E., Corcoran, D.L., Mukherjee, N., Skalsky, R.L., Hafner, M., Nusbaum, J.D.,
Shamulailatpam, P., Love, C.L., Dave, S.S., Tuschl, T., Ohler, U., Cullen, B.R., 2011.
Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell
lines. Cell Host Microbe. 10, 515–526.
Gottwein, E., Mukherjee, N., Sachse, C., Frenzel, C., Majoros, W.H., Chi, J.T., Braich, R.,
Manoharan, M., Soutschek, J., Ohler, U., Cullen, B.R., 2007. A viral microRNA
functions as an orthologue of cellular miR-155. Nature 450, 1096–1099.
Haq, K., Brisbin, J.T., Thanthrige-Don, N., Heidari, M., Sharif, S., 2010. Transcriptome
and proteome proﬁling of host responses to Marek's disease virus in chickens.
Vet. Immunol. Immunopathol. 138, 292–302.
Haecker, I., Gay, L.A., Yang, Y., Hu, J., Morse, A.M., McIntyre, L.M., Renne, R., 2012.
Ago HITS-CLIP expands understanding of Kaposi's sarcoma-associated herpes-
virus miRNA function in primary effusion lymphomas. PLoS Pathog. 8,
e1002884.
Heldin, C.H., Landstrom, M., Moustakas, A., 2009. Mechanism of TGF-beta signaling
to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin.
Cell. Biol. 21, 166–176.
Higgs, G., Slack, F., 2013. The multiple roles of microRNA-155 in oncogenesis. J. Clin.
Bioinform. 3, 17.
Katz, L.H., Li, Y., Chen, J.S., Munoz, N.M., Majumdar, A., Chen, J., Mishra, L., 2013.
Targeting TGF-beta signaling in cancer. Expert Opin. Ther. Targets 17, 743–760.
Kincaid, R.P., Sullivan, C.S., 2012. Virus-encoded microRNAs: an overview and a look
to the future. PLoS Pathog. 8, e1003018.
Kong, W., He, L., Richards, E.J., Challa, S., Xu, C.X., Permuth-Wey, J., Lancaster, J.M.,
Coppola, D., Sellers, T.A., Djeu, J.Y., Cheng, J.Q., 2014. Upregulation of miRNA-155
promotes tumour angiogenesis by targeting VHL and is associated with poor
prognosis and triple-negative breast cancer. Oncogene 33, 679–689.
Kozomara, A., Grifﬁths-Jones, S., 2011. miRBase: integrating microRNA annotation
and deep-sequencing data. Nucleic Acids Res. 39, D152–D157.
Kunec, D., 2013. Proteomics applied to avian herpesviruses. Avian Dis. 57, 351–359.
Lan, H.Y., Mu, W., Nikolic-Paterson, D.J., Atkins, R.C., 1995. A novel, simple, reliable,
and sensitive method for multiple immunoenzyme staining: use of microwave
oven heating to block antibody cross-reactivity and retrieve antigens.
J. Histochem. Cytochem. 43, 97–102.
Lei, X., Zhu, Y., Jones, T., Bai, Z., Huang, Y., Gao, S.J., 2012. A Kaposi's sarcoma-
associated herpesvirus microRNA and its variants target the transforming
growth factor beta pathway to promote cell survival. J. Virol. 86, 11698–11711.
Liu, Y., Sun, R., Lin, X., Liang, D., Deng, Q., Lan, K., 2012. Kaposi's sarcoma-associated
herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth
factor beta signaling through suppression of SMAD5. J. Virol. 86, 1372–1381.
Louaﬁ, F., Martinez-Nunez, R.T., Sanchez-Elsner, T., 2010. MicroRNA-155 targets
SMAD2 and modulates the response of macrophages to transforming growth
factor-{beta}. J. Biol. Chem. 285, 41328–41336.
Luo, J., Teng, M., Fan, J., Wang, F., Zhou, L., Deng, R., Zhang, G., 2010. Marek's disease
virus-encoded microRNAs: genomics, expression and function. Sci. China Life
Sci. 53, 1174–1180.
Luo, J., Sun, A.J., Teng, M., Zhou, H., Cui, Z.Z., Qu, L.H., Zhang, G.P., 2011. Expression
proﬁles of microRNAs encoded by the oncogenic Marek's disease virus reveal
two distinct expression patterns in vivo during different phases of disease.
J. Gen. Virol. 92, 608–620.
Massague, J., 2008. TGFbeta in cancer. Cell 134, 215–230.
Meyer, N., Penn, L.Z., 2008. Reﬂecting on 25 years with MYC. Nat. Rev. Cancer 8,
976–990.
Miyazono, K., Olofsson, A., Colosetti, P., Heldin, C.H., 1991. A role of the latent TGF-
beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10,
1091–1101.
Morgan, R., Anderson, A., Bernberg, E., Kamboj, S., Huang, E., Lagasse, G., Isaacs, G.,
Parcells, M., Meyers, B.C., Green, P.J., Burnside, J., 2008. Sequence conservation
and differential expression of Marek's disease virus microRNAs. J. Virol. 82,
12213–12220.
Moustakas, A., Pardali, K., Gaal, A., Heldin, C.H., 2002. Mechanisms of TGF-beta
signaling in regulation of cell growth and differentiation. Immunol. Lett. 82,
85–91.
Muylkens, B., Coupeau, D., Dambrine, G., Trapp, S., Rasschaert, D., 2010. Marek's
disease virus microRNA designated Mdv1-pre-miR-M4 targets both cellular and
viral genes. Arch. Virol. 155, 1823–1837.
Nair, V., Kung, H.J., 2004. Marek's disease virus oncogenicity: molecular mechan-
isms. In: Davison, F., Nair, V. (Eds.), Marek's Disease, An Evolving Problem.
Elsevier Academic Press, Oxford, pp. 32–48.
Osterrieder, N., Kamil, J.P., Schumacher, D., Tischer, B.K., Trapp, S., 2006. Marek's
disease virus: from miasma to model. Nat. Rev. Microbiol. 4, 283–294.
Parnas, O., Corcoran, D.L., Cullen, BR., 2014. Analysis of the mRNA targetome of
microRNAs expressed by Marek's disease virus. mBio 5, e01060–13.
Parvizi, P., Abdul-Careem, M.F., Haq, K., Thanthrige-Don, N., Schat, K.A., Sharif, S.,
2010. Immune responses against Marek's disease virus. Anim. Health Res. Rev.
11, 123–134.
Qian, Z., Brunovskis, P., Lee, L., Vogt, P.K., Kung, H.J., 1996. Novel DNA binding
speciﬁcities of a putative herpesvirus bZIP oncoprotein. J. Virol. 70, 7161–7170.
Rai, D., Kim, S.W., McKeller, M.R., Dahia, P.L., Aguiar, R.C., 2010. Targeting of SMAD5
links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc. Natl.
Acad. Sci. USA 107, 3111–3116.
Rehmsmeier, M., Steffen, P., Hochsmann, M., Giegerich, R., 2004. Fast and effective
prediction of microRNA/target duplexes. RNA 10, 1507–1517.
Rifkin, D.B., 2005. Latent transforming growth factor-beta (TGF-beta) binding
proteins: orchestrators of TGF-beta availability. J. Biol. Chem. 280, 7409–7412.
Ross, N.L., 1999. T-cell transformation by Marek's disease virus. Trends Microbiol. 7,
22–29.
Samols, M.A., Skalsky, R.L., Maldonado, A.M., Riva, A., Lopez, M.C., Baker, H.V.,
Renne, R., 2007. Identiﬁcation of cellular genes targeted by KSHV-encoded
microRNAs. PLoS Pathog. 3, e65.
Seoane, J., Le, H.V., Shen, L., Anderson, S.A., Massagué, J., 2004. Integration of Smad
and forkhead pathways in the control of neuroepithelial and glioblastoma cell
proliferation. Cell 117, 211–223.
Shi, Y., Massague, J., 2003. Mechanisms of TGF-beta signaling from cell membrane
to the nucleus. Cell 113, 685–700.
J.-Q. Chi et al. / Virology 476 (2015) 72–84 83
Skalsky, R.L., Samols, M.A., Plaisance, K.B., Boss, I.W., Riva, A., Lopez, M.C., Baker, H.V.,
Renne, R., 2007. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of
miR-155. J. Virol. 81, 12836–12845.
Stik, G., Laurent, S., Coupeau, D., Coutaud, B., Dambrine, G., Rasschaert, D.,
Muylkens, B., 2010. A p53-dependent promoter associated with polymorphic
tandem repeats controls the expression of a viral transcript encoding clustered
microRNAs. RNA 16, 2263–2276.
Stik, G., Dambrine, G., Pfeffer, S., Rasschaert, D., 2013. The oncogenic microRNA
OncomiR-21 overexpressed during Marek's disease lymphomagenesis is trans-
activated by the viral oncoprotein Meq. J. Virol. 87, 80–93.
Sun, A.J., Petherbridge, L., Zhao, Y.G., Li, Y.P., Nair, V., Cui, Z.Z., 2009. A BAC clone of
MDV strain GX0101 with REV-LTR integration retained its pathogenicity. Chin.
Sci. Bull. 54, 2641–2647.
Tam, W., Dahlberg, J.E., 2006. miR-155/BIC as an oncogenic microRNA. Genes
Chromosom. Cancer 45, 211–212.
Tili, E., Croce, C.M., Michaille, J.J., 2009. miR-155: on the crosstalk between
inﬂammation and cancer. Int. Rev. Immunol. 28, 264–284.
Waidner, L.A., Morgan, R.W., Anderson, A.S., Bernberg, E.L., Kamboj, S., Garcia, M.,
Riblet, S.M., Ouyang, M., Isaacs, G.K., Markis, M., Meyers, B.C., Green, P.J.,
Burnside, J., 2009. MicroRNAs of Gallid and Meleagrid herpesviruses show
generally conserved genomic locations and are virus-speciﬁc. Virology 388,
128–136.
Wu, K.J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., Dalla-
Favera, R., 1999. Direct activation of TERT transcription by c-MYC. Nat. Genet.
21, 220–224.
Xu, S., Xue, C., Li, J., Bi, Y., Cao, Y., 2011. Marek's disease virus type 1 microRNA miR-
M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the trans-
forming growth factor beta signal pathway. J. Virol. 85, 276–285.
Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., Miyazono, K.,
Kato, M., 2002. c-Myc is a downstream target of the Smad pathway. J. Biol.
Chem. 277, 854–861.
Yao, Y., Zhao, Y., Xu, H., Smith, L.P., Lawrie, C.H., Sewer, A., Zavolan, M., Nair, V., 2007.
Marek's disease virus type 2 (MDV-2)-encoded microRNAs show no sequence
conservation with those encoded by MDV-1. J. Virol. 81, 7164–7170.
Yao, Y., Zhao, Y., Xu, H., Smith, L.P., Lawrie, C.H., Watson, M., Nair, V., 2008.
MicroRNA proﬁle of Marek's disease virus-transformed T-cell line MSB-1:
predominance of virus-encoded microRNAs. J. Virol. 82, 4007–4015.
Yao, Y., Zhao, Y., Smith, L.P., Watson, M., Nair, V., 2009. Novel microRNAs (miRNAs)
encoded by herpesvirus of Turkeys: evidence of miRNA evolution by duplica-
tion. J. Virol. 83, 6969–6973.
Yin, Q., Wang, X., Fewell, C., Cameron, J., Zhu, H., Baddoo, M., Lin, Z., Flemington, E.K.,
2010. MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling
and BMP-mediated Epstein–Barr virus reactivation. J. Virol. 84, 6318–6327.
Yoshinaga, K., Obata, H., Jurukovski, V., Mazzieri, R., Chen, Y., Zilberberg, L., Huso, D.,
Melamed, J., Prijatelj, P., Todorovic, V., Dabovic, B., Rifkin, D.B., 2008. Perturba-
tion of transforming growth factor (TGF)-beta1 association with latent TGF-
beta binding protein yields inﬂammation and tumors. Proc. Natl. Acad. Sci. USA
105, 18758–18763.
Yu, Z.-H., Teng, M., Sun, A.-J., Yu, L.-L., Hu, B., Qu, L.-H., Ding, K., Cheng, X.-C., Liu, J.-X.,
Cui, Z.-Z., Zhang, G.-P., Luo, J., 2014. Virus-encoded miR-155 ortholog is an
important potential regulator but not essential for the development of lympho-
mas induced by very virulent Marek's disease virus. Virology 448, 55–64.
Yu, Z.H., Teng, M., Luo, J., Wang, X.W., Ding, K., Yu, L.L., Su, J.W., Chi, J.Q., Zhao, P., Hu,
B., Zhang, G.P., Liu, J.X., 2013. Molecular characteristics and evolutionary
analysis of ﬁeld Marek's disease virus prevalent in vaccinated chicken ﬂocks
in recent years in China. Virus Genes 47, 282–291.
Zhao, Y., Yao, Y., Xu, H., Lambeth, L., Smith, L.P., Kgosana, L., Wang, X., Nair, V., 2009.
A functional MicroRNA-155 ortholog encoded by the oncogenic Marek's disease
virus. J. Virol. 83, 489–492.
Zhao, Y., Xu, H., Yao, Y., Smith, L.P., Kgosana, L., Green, J., Petherbridge, L., Baigent, S.
J., Nair, V., 2011. Critical role of the virus-encoded microRNA-155 ortholog in
the induction of Marek’s disease lymphomas. PLoS Pathog. 7, e1001305.
J.-Q. Chi et al. / Virology 476 (2015) 72–8484
